Sirolimus Therapy of Focal Segmental Glomerulosclerosis Is Associated With Nephrotoxicity

American Journal of Kidney Diseases

Volumn 49, Issue 2, 2007, Pages 310-317

  Cho, Monique E ^a   Hurley, John K ^a   Kopp, Jeffrey B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

drug toxicity; fibrosis; glomerular filtration rate; Proteinuria

Indexed keywords

ANGIOTENSIN ANTAGONIST; CANDESARTAN; CAPTOPRIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LISINOPRIL; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUINAPRIL; RAPAMYCIN; TACROLIMUS; VALSARTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PROTEINURIA; REMISSION; SIDE EFFECT;

ADULT; FEMALE; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA; SIROLIMUS;

EID: 33846605083     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.10.020     Document Type: Article

References (32)

1. Kitiyakara C., Eggers P., and Kopp J.B. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44 (2004) 815-825
2. Korbet S.M., Schwartz M.M., and Lewis E.J. Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J Kidney Dis 23 (1994) 773-783
3. Rydel J.J., Korbet S.M., Borok R.Z., et al. Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25 (1995) 534-542
4. Chun M.J., Korbet S.M., Schwartz M.M., et al. Focal segmental glomerulosclerosis in nephrotic adults: Presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15 (2004) 2169-2177
5. Korbet S.M. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 23 (2003) 219-228
6. Cattran D.C., Appel G.B., Hebert L.A., et al., North America Nephrotic Syndrome Study Group. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 56 (1999) 2220-2226
7. Meyrier A., Noel L.H., Auriche P., et al., Collaborative Group of the Societe de Nephrologie. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 45 (1994) 1446-1456
8. Saunders R.N., Metcalfe M.S., and Nicholson M.L. Rapamycin in transplantation: A review of the evidence. Kidney Int 59 (2001) 3-16
9. Wang W., Chan Y.H., Lee W., et al. Effect of rapamycin and FK506 on mesangial cell proliferation. Transplant Proc 33 (2001) 1036-1037
10. Iwasaki H., Eguchi S., Ueno H., et al. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 140 (1999) 4659-4668
11. Marx S.O., Jayaraman T., Go L.O., et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
12. Jain S., Bicknell G.R., Whiting P.H., et al. Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 33 (2001) 556-558
13. Zhu J., Wu J., Frizell E., et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117 (1999) 1198-1204
14. Kambham N., Markowitz G.S., Valeri A.M., et al. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59 (2001) 1498-1509
15. Daniel C., Ziswiler R., Frey B., et al. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 8 (2000) 52-62
16. Tao Y., Kim J., Schrier R.W., et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16 (2005) 46-51
17. Bonegio R.G., Fuhro R., Wang Z., et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16 (2005) 2063-2072
18. Lieberthal W., Fuhro R., Andry C.C., et al. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281 (2001) F693-F706
19. Andoh T.F., Burdmann E.A., Fransechini N., et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50 (1996) 1110-1117
20. Fervenza F.C., Fitzpatrick P.M., Mertz J., et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19 (2004) 1288-1292
21. Marti H.P., and Frey F.J. Nephrotoxicity of rapamycin: An emerging problem in clinical medicine. Nephrol Dial Transplant 20 (2005) 13-15
22. McTaggart R.A., Gottlieb D., Brooks J., et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3 (2003) 416-423
23. Zakliczynski M., Nozynski J., Zakliczynska H., et al. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 35 (2003) 2331-2332
24. Kaplan B., Schold J., Srinivas T., et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 4 (2004) 1709-1712
25. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 78 (2004) 1362-1366
26. Hadaya K., Wissin M., Emine B., et al. Conversion to sirolimus after renal transplantation: High failure rate due to nephrotic proteinuria and other adverse events. J Am Soc Nephrol 14 (2003) 185A (abstr)
27. Jim B., Doyle A., and Bloom R.D. Rapamycin is associated with worsening proteinuria in transplant patients with renal injury: a report of four cases. J Am Soc Nephrol 14 (2003) 65A (abstr)
28. Perlman A., Moore J., Kim E., et al. Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients. J Am Soc Nephrol 14 (2003) 645A (abstr)
29. Tumlin J.A., Miller D., Near M., et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1 (2006) 109-116
30. Zandi-Nejad K., Eddy A.A., Glassock R.J., et al. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl 92 (2004) S76-S89
31. Thomas M.E., Brunskill N.J., Harris K.P., et al. Proteinuria induces tubular cell turnover: A potential mechanism for tubular atrophy. Kidney Int 55 (1999) 890-898
32. Burton C.J., Harper S.J., Bailey E., et al. Turnover of human tubular cells exposed to proteins in vivo and in vitro. Kidney Int 59 (2001) 507-514